11整形外科例会.indd

Size: px
Start display at page:

Download "11整形外科例会.indd"

Transcription

1 p75ntr 4 : CCI 7 p l cat walk von Frey test C7GFAP Iba1 DRG C7 ATF3 CGRP GFAP p75ntr 2 Frohse : 5 sliding sliding Z sliding 6 : OA HA OA CatWalk system HA

2 MRI MRI MRI 8 Mmp13short interfering RNA sirna MMP-13 OA OA Mmp13 OAOA Mmp13short interfering RNA sirna in vivo Mmp13OA 9 : 10 MRI MRI MRI 11 Platelet Rich Plasma PRP PRP PRP Selzer PRP 12 : OAI OAI 3 KLgrade MRIgrade 1 2 grade D-2D registration 3D-2D registration OA

3 Kellgren-Lawrencegrade 1 2 OA CT/ X 14 3DCTS1 S1 PAS1 S1 S1 S1 3DCT Xray sum image far-out syndrome far-out syndrome 7 3DMRI 3DCT OsiriX Wiltze approach TNFα 10 ADL

4 : Diffusion Tensor Imaging Diffuison Tensor Imaging DTI fractional anisotorophy FA DTI FA ADC DTI 21 : DXA CT Frankel B 3 C 1 D 4 E THA 3D THA 3 Zed Hip Lexi 3D 3D 3D 26 : 2 39 Gap Tension Gap 1020Tension / 23 Tension Tension 2 4 instrumentation 6 instrumentation 1 instrumentation 6

5 AMIS Anterior Minimally Invasive Surgery : 1 30 THA Minimally invasive surgery-tha AMIS THA 28 in-situ pinning SCFEISP ISP BMI PTA 29 Buck 2006 Buck PSO VCR 10 SVA126CA23LL5.7PT49 SVA27CA8LL30PT30 31 Cortical Bone Trajectory Cortical bone trajectory CBT2009Santoni mini open DLIF Direct lateral interbody fusion DLIF mini open DLIF

6 JOABPEQ JOABPEQ 4 20 VAS 11/100 50/ : VAS VAS Th11 QOL PMDA PMDA

7 subsynovial connective tissue SSCT CTSSSCT CTS CTS 41 CPPD 1 85 PIP/DIP XCT DRUJ /3DCT DRUJ CPPD Wolfe Grade 43 needle fasciotomy 25G Tubiana stage stage 1: 4 2: 3 3: 2 4: 1 Total Flexion Deformity Sauve-Kapanji DRUJ OA S-K 12 12

8 Locking Plate CT 5 5 CT Plate 46 Sham Na DRGCGRP Sham Na CGRP 47 Cat Walk TNF-α TNF-α : in vivo in vitro in vivo in vitro 50 : Drop-mass TNFα SDL4/5 FluoroGold 23G /Kg 0.4 /Kg 4 /Kg + 1 L1-L6 CGRP CGRPFG CGRP

9 NGF NGF NGF NGF 53 G-CSF G-CSF G-CSF G-CSF Below-level Allodynia Microglia G-CSF 54 Noggin RT-PCR Noggin NogginNoggin 55 : C2/ C2/3 C2/3

10 JOA 12.5/17C4 5 6 C MRI C3/4 5/6 C2-T1Occ-T2 C : G-CSF G-CSF34 1 JOA 4 V 4 A V AASIA G-CSF 62 G-CSF : MRI Th10 L1 Critical Point T G-CSF G-CSF 17G-CSFControl 24 ASIA score AIS Motor Score G-CSF 1 1 G-CSF 1 G-CSF RB 65 RB 29RB RB 20RB 8 8

11 OPLL 29CSM 82JOA score C5 3 9 JOA scoreopll: CSM: C PPS extender 2 3 OPLL CT Cine-MRI Cine-MRI FIESTA : MRI MRIT T2 T2

12 MI MRI US US MI US MI 71 PCL TKA KL grade 72 TKA TKA TATA TA 1,0002,000 1,000 TA 1,000 TA 73 B RA B HBV de novo BRA HBV RA HBV Infliximab 27etanercept 47 adalimumab 12tocilizumab 6 abatacept 2 TKA40THA

13 Accessory AnteroLateral Talar Facet AALTF peroneal spasm peroneal spastic flatfoot Laaveg-Ponseti score score ADL X MRI MRI T1 T2 HA block 1 9

14 Injury Severity Score ISS16 ISS CT CT 84 PHILOS Proximal Humeral Internal Locking System PHILOS PHILOS X Polish taper cemented stem Polish taper cemented stem 1 X 2 Exeter stem

15 AO/OTA 41; 2 42; 2143; 6 44; 2 90 Supra-Patellar Approach 91 MRI MRA MRIMRI 174 anterior knee pain Supra-patellar approach

: cadaver 3 Camitz CamitzCamitz Burkhalter 3 fresh frozen cadaverfastrak 7 Hypertrophic Thener Muscle: Hypertrohpic Thener muscle 15 28HM 6

: cadaver 3 Camitz CamitzCamitz Burkhalter 3 fresh frozen cadaverfastrak 7 Hypertrophic Thener Muscle: Hypertrohpic Thener muscle 15 28HM 6 92 107 120 2016 1322 27 12 5 7 30 27 12 6 7 30 3 F 1 HGF HGF sham cut control 10 l cut NSHGF 100 g/10 l cut HGF 4 2 ipsschwann : 3 ips Schwann ips Schwann NCSC NCSC 3 Krackow weave technique Krackow K

More information

218 1304 7 p75ntr BPA DRG p75ntrp75ntr Sham BPA 1 ShamC7 8DRG C7 BPA C7DRG C7 ELISA p75ntr 8 : OAI OAOAI baselinexkellgren/lawrence grade 0/1 48grade

218 1304 7 p75ntr BPA DRG p75ntrp75ntr Sham BPA 1 ShamC7 8DRG C7 BPA C7DRG C7 ELISA p75ntr 8 : OAI OAOAI baselinexkellgren/lawrence grade 0/1 48grade 91 217 231 2015 1304 26 12 137 30 26 12 147 30 1 1 FCU FDSmotor branch 3 6 2 Krackow Krackow 4 Krackow K 2 weaves interlacing suture 5 75N 200K Krackow 3 Hyperthenar muscle Hypertrophic thenar muscle HTM

More information

MISS Voice 4 MISt QOL (PPS) MISt MISt MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL QOL MISt MIS

MISS Voice 4 MISt QOL (PPS) MISt MISt   MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL QOL MISt MIS Vol.4 MISt (Minimally Invasive Spine Stabilization: MISt ) MISt MISS Voice 4 MISt QOL (PPS) MISt MISt http://mist.umin.jp MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL

More information

慢性関節リウマチ患者における人工肘関節置換術後の一症例

慢性関節リウマチ患者における人工肘関節置換術後の一症例 KEY WORDS RA TEA 1 1 1 1 1 1 1 (MD) 1 (MD) 1 (MD) 1 1 52 31 RA Steinbrocker stageclass 2004.6.30 TEA Darrach 7.5 PROM-T 80 65 85(P) 30(P) 30 20(P) 45 0 MMT JOA 42 2 3 Active 5 Passive 6 ROM-T 75 75 135

More information

障害者職域拡大カリキュラム研究会中間報告書構成案

障害者職域拡大カリキュラム研究会中間報告書構成案 3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16

More information

京阪神集談会2.indd

京阪神集談会2.indd F hemangioblastoma elastofibroma Kaschin- Beck, Werner carpal boss Kienbock,SAPHO super bone scan F L/, precoat stem TKAMCL.,Dewar,.,PIPtumoral calcinosis. F Castleman RAO RASauve-Kapandji -L- (HAGL lesion)

More information

Quadrilateral space syndromeに広背筋部痛を合併した投球障害肩の一症例

Quadrilateral space syndromeに広背筋部痛を合併した投球障害肩の一症例 ) ) ) ) (MD) 1) 2) winging 10 1 7 12 one point early cocking phase follow through phase winging MMT SSP testspeed testimpingement sign winging 7 26 MMT 3 2 8 17 3 2 winging scapula winging winging (MD)

More information

胸腺摘出後胸郭出口症候群牽引型を呈した一症例

胸腺摘出後胸郭出口症候群牽引型を呈した一症例 1) 11 12 14 56 13 4 3 67nM 5 30 nm winging morley inferior stress TOS TOS 58 VAS 40 ROM 100 160 MMT 3 Cuff 3 Cuff 4 TOS 82 VAS 0 ROM 175 MMT 4 3+ Cuff 3+ b 1 2part PT 2part 2 stooping ex's 2.5 1 67 2 75

More information

QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12

QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12 54 1 2018 2 4-1 OK-432 1 15 14 15 US CT MRI 17 cm 0.16 g/kg/day OK-432 3 1 ke 2 2 ke 3 1 1,150 ml 13 US OK-432 4-2 TJ-28 TJ-28 2003 3 2017 6 250 TJ-28 44 16 28 TJ-28 7 2 46 8.5 2 2 9 34 79.1 10 23.3 34

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

NCB Periprosthetic Femur Plate System 手技書

NCB Periprosthetic Femur Plate System 手技書 NCB Periprosthetic Femur Plate System NCB 販売名 :NCB Periprosthetic Femur プレート NCB プレーティングシステム GTR ケーブルグリップシステム 禁忌 警告 予防措置を含む製品情報が添付文書に記載されています 使用前は必ず参照して下さい NCB Periprosthetic Femur Plate System 1 NCB 2

More information

9 月 11 日 ( 金 ) 第 1 会場 8:50 9:00 開会にあたって 41 9:05 9:25 GOTS Traveling Fellow 報告 GT-1 GT-2 9:35 10:35 特別講演 SL-1 10:45 11:45 特別講演 SL-2 12

9 月 11 日 ( 金 ) 第 1 会場 8:50 9:00 開会にあたって 41 9:05 9:25 GOTS Traveling Fellow 報告 GT-1 GT-2 9:35 10:35 特別講演 SL-1 10:45 11:45 特別講演 SL-2 12 プログラム第 1 日 /9 月 11 日 ( 金 ) 9 月 11 日 ( 金 ) 第 1 会場 8:50 9:00 開会にあたって 41 9:05 9:25 GOTS Traveling Fellow 報告 GT-1 GT-2 9:35 10:35 特別講演 1 231 SL-1 10:45 11:45 特別講演 2 2020 232 SL-2 12:00 13:00 ランチョンセミナー 1 233

More information

がん診療におけるFDG FDG-PET/CTの役割

がん診療におけるFDG FDG-PET/CTの役割 PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT

More information

OLIF Hybrid PF 2012 OLIF 1, 2 OLIF OLIF OLIF Open Hybrid Rigidity, Single stage Two-stage MIS 1, 2 MIS Sagittal Adjusting Screw SAS + LONGITUDE II Dir

OLIF Hybrid PF 2012 OLIF 1, 2 OLIF OLIF OLIF Open Hybrid Rigidity, Single stage Two-stage MIS 1, 2 MIS Sagittal Adjusting Screw SAS + LONGITUDE II Dir OLIF Hybrid PF CLYDESDALE Spinal System CAPSTONE PTC Spinal System Gary K. Michelson, M.D. OLIF Hybrid PF 2012 OLIF 1, 2 OLIF OLIF OLIF Open Hybrid Rigidity, Single stage Two-stage MIS 1, 2 MIS Sagittal

More information

untitled

untitled 5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm

More information

Microsoft Word - No.1武村.doc

Microsoft Word - No.1武村.doc 1) 1) 1) 2) 2) 2) 1) 2) 23 31.15% 23.1% () 2009 4 2011 8 65 ( ) ( ) 2 BMI (FIM ) 89 45 44 83.48 8.55 (p=0.66) 87.11 5.53 (p=0.39) 19 26 9 35 (P

More information

CONTENTS I 2 3 6 6 9 12 17 24 Henry 26 28 29 30 35 35 39 43 II 48 55 60 67 67 70 74 80 87 94 100 AO A MIPO minimally invasive plate osteosynthesisao A AO B 3 AO C 108 Monteggia 113 X 122 123 AOL 126 127

More information

Spinal Surgery 標準治療と明日の医療を考える 誌上フォーラム Forum Stratagies & Indications vol.1 上位頚椎の事故外傷 招待コメンテーター : 鈴木晋介 ( 仙台医療センター ) 企画 コメント : 乾敏彦 ( 冨永病

Spinal Surgery 標準治療と明日の医療を考える 誌上フォーラム Forum Stratagies & Indications vol.1 上位頚椎の事故外傷 招待コメンテーター : 鈴木晋介 ( 仙台医療センター ) 企画 コメント : 乾敏彦 ( 冨永病 Spinal Surgery 26 1 30 38 2012 標準治療と明日の医療を考える 誌上フォーラム Forum Stratagies & Indications vol.1 上位頚椎の事故外傷 招待コメンテーター : 鈴木晋介 ( 仙台医療センター ) 企画 コメント : 乾敏彦 ( 冨永病院脳神経外科 ) 下川宣幸 ( ツカザキ病院脳神経外科 ) 菅原卓 ( 秋田大学脳神経外科 ) 症例提供

More information

CONTENTS I 2 3 Guyon 6 8 11 4 17 DRUJ TFCC 21 22 3 4 RCJ 4 5 6R 27 MCR MCJ MCU 29 DRUJ DRUJ 31 34 MP 35 MP PIP 38 PIP DIP 40 42 DIP PIP II 48 55 extension block pin 62 69 75 82 mini-octr 89 Snake 94 X

More information

2

2 2 ( ) 1.5 6.0 ( 3.0 3.0 ) 2.0 5.0 ( 2.2 2.8 ) 2.5 4.5 ( 1.8 2.7 ) 3.0 4.0 ( 1.4 2.6 ) 3 4 5 6 1. 2. (1) (2) (3) (4) 3. (1) (3) 7 8 9 10 11 12 13 P28 1. 621013 3 1017 1019 3 14 15 16 17 18 ( ) 1.5 6.0 (

More information

081203_1837

081203_1837 A 8:30 8:45 PL 1 12 11 11 8:45 11:15 SS-1 SS-2 SS-3 SS-4 SS-5 SS-6 Treatment of DDH after walking age Shriners Hosp. for Children, Los Angeles, USAColin F. Moseley DDH treatment after walking age analysis

More information

橡Taro10-大豆研究図表込み.PDF

橡Taro10-大豆研究図表込み.PDF 100 t 48 19 12 500 t 1960 28 90 2 3 1960 64 75 15 1987 29-55- 4,386 3,453 825 208 617 9 55 5,017 3,898 945 189 464 89 203 8 70 4,821 3,630 994 196 494 107 197 8 95 4,628 3,426 1,013 193 494 108 218 7 95

More information

2 1 2 3 27 2 6 2 5 19 50 1 2

2 1 2 3 27 2 6 2 5 19 50 1 2 1 2 1 2 3 27 2 6 2 5 19 50 1 2 2 17 1 5 6 5 6 3 5 5 20 5 5 5 4 1 5 18 18 6 6 7 8 TA 1 2 9 36 36 19 36 1 2 3 4 9 5 10 10 11 2 27 12 17 13 6 30 16 15 14 15 16 17 18 19 28 34 20 50 50 5 6 3 21 40 1 22 23

More information

Aesculap BiCONTACT Life goes on where bone remains Orthopaedics

Aesculap BiCONTACT Life goes on where bone remains Orthopaedics Aesculap BiCONTACT Life goes on where bone remains Orthopaedics icontact Life goes on where bone remains Total Hip System Introduction 1987 BiCONTACT 32,000 700,000 *2013 3 2 Objective Indication Implantation

More information

89 91 93 95 97 99 101 103 105 107 109 111 113 115 H 117 119 l l 121 l l 123 125 127 129 l l l l 131 kl kl kl kl 133 135 137 139 141 143 145 147 149 151 153 155 157 159

More information

株式会社日清製粉グループ本社 第158期中間事業報告書

株式会社日清製粉グループ本社 第158期中間事業報告書 C O N T E N T S...1...3...5...7...9...11...12...13...14 1 2 3 4 3.7% 5.8% 8.5% 70,100kL 81.2% 0.8% 25 20 15 10 5 0 9.18 9.54 9.74 9.62 9.65 9.71 21.04 21.97 22.44 22.23 8.54 22.31 22.45 20.41 15 12 9 6

More information

untitled

untitled --...- 2 -...- 2 -...- 2 -...- 3 -...- 3 -...- 7 -... - 11 -...- 13 -...- 16 -...- 17 -...- 19 -...- 20 -...- 22 -...- 23 -...- 27 -...- 28 -...- 31 -...- 33 -...- 39 -...- 42 -...- 43 - ...- 47 -...-

More information

- 111 -

- 111 - - 110 - - 111 - - 112 - - 113 - - 114 - - 115 - - 116 - - 117 - - 118 - - 119 - - 120 - - 121 - - 122 - - 123 - - 124 - - 125 - - 126 - - 127 - - 128 - - 129 - - 130 - - 131 - - 132 - - 133 - - 134 - -

More information

2 3 2

2 3 2 1 2 3 2 ha ha ha 3 4 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 5 5 ( ) ( ) 3 ( ) ( ),,, 5 6 7 ( ) ( ) ( ) ( ) ( ) ( ) 6 36.3% ( ) 8 ( ) ( ) ( ) ( ) ( ) ( ) 3 5 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )

More information

300 10

300 10 300 10 16 1695 4 2 44 7 3 1 2 2 1869 11 192210 506.75ha 3 (1594) (1596) 16 17 7 1630 2 14 1637 16 17 4 1664 5 6 1678 6 1678 6 3 8 16954 8 (1758) 7 (1770) 17 2 (1745) 2 (1765) 4 11 11 10 12 1 12 12 12 2

More information

untitled

untitled 2 23 3 28 10 12 1 2 3 18 6 1 1 2 9 9 5 22 1 22 10 2 100 9 9 9 1 11 2,300 22 10 8 90 5 80 90 100 5,000 100 90 5 90 8 90 13 1 22 20 / 14 / 10 / 1 13 80 8 80 80 7 8 13 80 7 90 2 200 300 3 4 10 1 1 90 5 90

More information

- 8 -. 1 (1) (2) (3) (4) (5) (6) (7) (8)

- 8 -. 1 (1) (2) (3) (4) (5) (6) (7) (8) - 7 - (1) (2).. ha 43 ( (1) ( ) (2).. 18 11 30 43 (1).. (2).. 0.5. () () A) B) C) - 8 -. 1 (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) 43-9 - - 10 - (1).. 43.. 43... 43 - 11 - (2) (1).. A B A A B A - 12 -.

More information

第1 予算編成の基本的な考え方

第1 予算編成の基本的な考え方 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - ) () (

More information

0

0 ... 1... 2... 3... 5... 10... 13... 15... 19... 22... 24... 26... 27 0 0 1 2 H13 12 3 4 H21 15.7 5 29.8 10 1 6 4 1 10 1 50,284 48,834 46,185 41,056 33,892 26,726 7 8 9 1012 10 11 12 136ha 80.7ha 13 14

More information

untitled

untitled 1,985ha 41.5 2,799ha 58.5 4,784ha 100.0 3 14,210 0 0.0 27 57,590 37,140 64.5 3 1,800 930 51.7 6 1,150 1,150 31.0 39 77,310 39,220 50.7 34 8-3 34 8-4 52 1-6 52 2-3 53 1-6 56 1-2 56 1 18 12 17 30 50

More information

9 5 1 9 30 17 10 1 21 30 18 10 1 22 30 18 10 1 20 30 16 10 1 20 30 31 16 60 9 63 9 65 9 3 14 1 2 3 4 19 10 1 5,600 20,000 21,500 10 10 1,540 1,540 950 950 178 15 5,329 19 1,900 200 19 12 1 200 3,429

More information

0.表紙

0.表紙 60 10 11 11 11,600 36,500 10,500 7,900 +1,500+1,500+9,000+18,0003,70041,600 12 3.84ha 3,100 3,100 4,400 2,785 5,000 50 70 3,500 3,500 2,600 30 2,600 45 3,375 40 4,500 20 2,000 12 1,500 12 2,300 7,500

More information

1 4 8 19 65 87 108 132 142 156 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - 30-19 - - 20 - ( ) - 21 - - 22 - - 23 - - 24 -

More information

-2-

-2- -1- -2- -3-24 32ha 13-4- 30-5- -6- -7- 100-8- 20 20 100-9- 100-10- 100 100-11- -12-30 -13- 10-14- 52 71 59-15- 30-16- -17- -18- 31 31-19- -20- 47 52 71 29 41 59 306 88 348-21- -22- -23- -24- 12-25- 1,300

More information

総務委員会会議録

総務委員会会議録 29 28 29 29 () 121 1 111 11928 3 () () () () 11928 3 1,320 32,7897,000 () 1 23725,000 9 1,320 313 2,7897,000 2 2 2 5.5 16 15200 31 29 2931 3110 21 21 5 6 8,2195,000 2134,1097,000 1,320 32,7897,000 31 ()

More information

100 26331 26331 7,082ha(6.9% 9,027ha(8.8) 903ha(0.9%) 1,2292.5% 5,45711.2% 2,916(6.0%) 80,622ha79.0 4,507ha4.4% 18,277(37.4) 2949 (42.9% ( ) !! 1008940 (03)3581-4111 http://www.mof.go.jp/ 0608579

More information

14 12 ( 17 4 2 ) 2004

14 12 ( 17 4 2 ) 2004 14 12 ( 17 4 2 ) 2004 1 4,700 1980 1,757 1,150 25,000ha 6,000ha 10 10 10 2 1981 56 90 4,700 1980 1,757 1,150 2003 187,614 96,940 51.7 17 102,128 54.7 2004 545 76 14 2004 4 13 49.1 1981 84,638 38,272 17,570

More information

,

, 34 29 5 29 6 29 7 30 28 26 1 1-71 - , - 72 - 27 3 1, - 73 - 5811 5821 5822 5831 58 2 5841 5851 5861 5862 5863 5864 5892 5896 5897 5898 5891 5895 7711 622 6311 6312 6314 6324 6032 6033 7611 7621 7623 7624

More information

医療レーザー脱毛の威力と限界

医療レーザー脱毛の威力と限界 .... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.

More information

Low Friction Anatomic 1

Low Friction Anatomic 1 Ver.6.2 LFA Total Knee System Low Friction Anatomic 1 Low Friction Advanced Ceramic Technology Anatomic Modular System 2 3 0.1 0-0.1-0.2-0.3-0.4 0 50 100 150 200 4 5 6 A3 A5 A4 A2 A1 Anterior Med. Lat.

More information

無印良品のスキンケア

無印良品のスキンケア 2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240

More information

gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide

More information

(1)〜(4)/松尾

(1)〜(4)/松尾 kcalkcal SV SV SV BMI BMI SV SV SV kcal kcal kcal kcal SV SV kcal SV SV SV SVSV SV SV SV SVSV SV SV SV SV SV SV SV SV SV SV SV SV SV SV BMI BMI BMI BMI (ADL kcal SV SV SV SV SV BMI kcal kcal BMI

More information

第2巻/1-5

第2巻/1-5 79 32 6 80 1998 1997 4 PTA 80 1 2 5 81 82 3 82 14.9 1 51.9 33.8 58.4 26.3 14.5 59.4 21 PTA 5 83 3 84 3 3 5 85 52.5 PTA 9,864 11 39 105 120 2,099 2,763 3 2 38 26 24 86 4 1 17 5 87 88 3 2,000 110 1991 5

More information

18 (1) US (2) US US US 90 (3) 2 8 1 18 108 2 2,000 3 6,000 4 33 2 17 5 2 3 1 2 8 6 7 7 2 2,000 8 1 8 19 9 10 2 2 7 11 2 12 28 1 2 11 7 1 1 1 1 1 1 3 2 3 33 2 1 3 2 3 2 16 2 8 3 28 8 3 5 13 1 14 15 1 2

More information

Microsoft PowerPoint - 201409_秀英体の取組み素材(予稿集).ppt

Microsoft PowerPoint - 201409_秀英体の取組み素材(予稿集).ppt 1 2 3 4 5 6 7 8 9 10 11 No Image No Image 12 13 14 15 16 17 18 19 20 21 22 23 No Image No Image No Image No Image 24 No Image No Image No Image No Image 25 No Image No Image No Image No Image 26 27 28

More information

第15回整形外科リハビリテーション研究会

第15回整形外科リハビリテーション研究会 ( ) 30 17 Neer 3part 58 2 90 40 1st 15 0 20 1 pull-out 10 229 165 160 60 Th10JOA 95 7 proximal amplitude( ) distal excursion( ) 3 Ideberg Type 150 1st 0 L4 Bankart KEY WORDS Bankart IGHL 1 1 1 1 1 1 1

More information

200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,

More information

1 1 1 (1) 1 (2) 1 (3) 2 (4) 2 (5) 3 (6) 3 (7) 4 (8) 4 5 (1) 5 (2) 6 7 7 7 7 8 11 12 12 13 13 13 14 14

1 1 1 (1) 1 (2) 1 (3) 2 (4) 2 (5) 3 (6) 3 (7) 4 (8) 4 5 (1) 5 (2) 6 7 7 7 7 8 11 12 12 13 13 13 14 14 1 1 1 (1) 1 (2) 1 (3) 2 (4) 2 (5) 3 (6) 3 (7) 4 (8) 4 5 (1) 5 (2) 6 7 7 7 7 8 11 12 12 13 13 13 14 14 14 14 15 16 16 20 24 26 29 32 32 37 39 41 43 46 46 48 50 55 57 57 65 66 76 77 77 79 81 84 86 88 88

More information

untitled

untitled PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 22 NO. 1 (35 53) ether-à-go-go + + + + + + + + + > > + > in vivoin vitro In vivo + + + + + + + + in vivo = + = = = + + + + + + + + + + + + + + + + + + +

More information

野岩鉄道の旅

野岩鉄道の旅 29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15

More information

16 41 17 22 12 10

16 41 17 22 12 10 1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6

More information

製品案内 価格表 2014/4/1

製品案内 価格表 2014/4/1 4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(

More information